Short-term cannabis products may reduce a marker of bone breakdown in healthy adults

In two Phase 1 trials of 83 healthy adults, one week of oral THC- or CBD-dominant cannabis products reduced a marker of bone resorption compared to placebo, providing the first human evidence that cannabinoids may affect bone turnover.

Kulpa, Justyna et al.·Cannabis and cannabinoid research·2024·Preliminary Evidencerandomized controlled trial
RTHC-05444Randomized controlled trialPreliminary Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
randomized controlled trial
Evidence
Preliminary Evidence
Sample
N=38

What This Study Found

After 7 days of treatment, the bone resorption marker CTx was significantly lower in the THC-dominant product group (Spectrum Red) versus placebo (b = -164.28, p = 0.04) and marginally lower in the CBD-dominant group (Spectrum Yellow, p = 0.06). No significant differences were found for bone formation markers (P1NP, ALP).

Key Numbers

83 participants (38 men, 45 women); 7 days of treatment; CTx (bone resorption) significantly reduced by Spectrum Red (p = 0.04); marginally reduced by Spectrum Yellow (p = 0.06); no changes in P1NP or ALP (bone formation markers); all bone markers higher in men at baseline

How They Did This

Secondary analysis of two Phase 1 double-blind, placebo-controlled trials. 83 healthy participants (38 men, 45 women) were randomized to receive 5-20 mg THC daily (with varying CBD levels) or placebo for 7 days. Bone markers were assessed at baseline, day 8, and after 5-day washout.

Why This Research Matters

These are the first interventional human data on cannabinoid effects on bone turnover. The reduction in bone resorption without affecting bone formation is a pattern consistent with bone-protective properties.

The Bigger Picture

If cannabinoids reduce bone breakdown, they could have therapeutic potential for osteoporosis and other bone conditions. This preliminary human evidence supports further research in populations with bone disease.

What This Study Doesn't Tell Us

Very short treatment duration (7 days); healthy participants not bone-disease patients; small sample; secondary analysis not primary endpoint; changes not considered clinically significant; cannot determine which cannabinoid (THC or CBD) drove effects

Questions This Raises

  • ?Would longer treatment produce clinically meaningful bone effects?
  • ?Would people with osteoporosis show a greater response?
  • ?Is the effect driven by THC, CBD, or their combination?

Trust & Context

Key Stat:
First human data on cannabinoid effects on bone markers
Evidence Grade:
Randomized, placebo-controlled Phase 1 data, but very short duration, healthy participants, and secondary analysis.
Study Age:
2024 study
Original Title:
Serum Markers of Bone Turnover Following Controlled Administration of Two Medical Cannabis Products in Healthy Adults.
Published In:
Cannabis and cannabinoid research, 9(1), 300-309 (2024)
Database ID:
RTHC-05444

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Could cannabis help protect bones?

This study provides the first human evidence suggesting it might. After just one week, participants taking cannabis products showed reduced levels of a marker that indicates bone breakdown. However, the changes were small and not considered clinically significant, and the study was done in healthy people, not those with bone disease.

Which cannabis product showed the effect?

The THC-dominant product (Spectrum Red, 2.5 mg THC/0.3 mg CBD per softgel) showed a statistically significant reduction in the bone resorption marker. The CBD-dominant product (Spectrum Yellow, 20 mg CBD/0.9 mg THC per mL) showed a similar trend that fell just short of significance.

Read More on RethinkTHC

Cite This Study

RTHC-05444·https://rethinkthc.com/research/RTHC-05444

APA

Kulpa, Justyna; Eglit, Graham; Hill, Melanie L; MacNair, Laura; Yardley, Helena; Ware, Mark A; Bonn-Miller, Marcel O; Peters, Erica N. (2024). Serum Markers of Bone Turnover Following Controlled Administration of Two Medical Cannabis Products in Healthy Adults.. Cannabis and cannabinoid research, 9(1), 300-309. https://doi.org/10.1089/can.2022.0181

MLA

Kulpa, Justyna, et al. "Serum Markers of Bone Turnover Following Controlled Administration of Two Medical Cannabis Products in Healthy Adults.." Cannabis and cannabinoid research, 2024. https://doi.org/10.1089/can.2022.0181

RethinkTHC

RethinkTHC Research Database. "Serum Markers of Bone Turnover Following Controlled Administ..." RTHC-05444. Retrieved from https://rethinkthc.com/research/kulpa-2024-serum-markers-of-bone

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.